Description: Deze website is niet actief.
Frame Therapeutics B.V. is now CureVac Netherlands B.V. Personalized anti-cancer therapy, maximizing immunogenicity. Updates July 1, 2022
July 1st marks the official closing of the acquisition deal between CureVac NV and Frame Therapeutics BV. Frame will continue as a legal entity under the name CureVac Netherlands BV. This Dutch legal entity is a full subsidiary of the German holding CureVac AG . The Managing Board of CureVac Netherlands BV will consist of Prof. Ronald Plasterk and Dr. Wigard Kloosterman. The Supervisory Board will consist of Dr. Franz-Werner Haas (CEO), Pierre Kemula (CFO), and Dr. Marco Rau (General Counsel).
Frame Therapeutics is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. We are developing personalized cancer immunotherapies , that are designed based on the Frame neoantigens uniquely encoded by the genome of each patient's tumor.